贝达药业股价跌5.01%，广发基金旗下1只基金重仓，持有4700股浮亏损失1.35万元

Core Viewpoint - Benda Pharmaceutical experienced a decline of 5.01% in stock price, reaching 54.59 CNY per share, with a trading volume of 603 million CNY and a turnover rate of 2.60%, resulting in a total market capitalization of 22.968 billion CNY [1] Company Overview - Benda Pharmaceutical Co., Ltd. is located in Hangzhou, Zhejiang Province, and was established on January 7, 2003, with its listing date on November 7, 2016 [1] - The company's main business involves the research, production, and sales of pharmaceuticals, with 99.10% of its revenue coming from drug sales and 0.90% from other supplementary sources [1] Fund Holdings - According to data, one fund under GF Fund has a significant holding in Benda Pharmaceutical. The GF Stable Growth Mixed A Fund (002622) held 4,700 shares in the second quarter, accounting for 0.49% of the fund's net value, ranking as the fifth-largest holding [2] - The GF Stable Growth Mixed A Fund was established on June 27, 2016, with a latest scale of 55.5805 million CNY. Year-to-date returns are 4.55%, ranking 6963 out of 8155 in its category, while the one-year return is 4.95%, ranking 6942 out of 8029 [2] - The fund manager, Qiu Shilei, has been in position for 9 years and 276 days, with total assets under management of 552 million CNY. The best fund return during his tenure is 64.45%, while the worst is 0.28% [2]